Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

JF. Vansteenkiste, BC. Cho, T. Vanakesa, T. De Pas, M. Zielinski, MS. Kim, J. Jassem, M. Yoshimura, J. Dahabreh, H. Nakayama, L. Havel, H. Kondo, T. Mitsudomi, K. Zarogoulidis, OA. Gladkov, K. Udud, H. Tada, H. Hoffman, A. Bugge, P. Taylor, EE....

. 2016 ; 17 (6) : 822-35. [pub] 20160427

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024025
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 27132212
DOI 10.1016/s1470-2045(16)00099-1
Knihovny.cz E-zdroje

BACKGROUND: Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made in adjuvant treatment. We aimed to assess the efficacy of the MAGE-A3 cancer immunotherapeutic in surgically resected NSCLC. METHODS: In this randomised, double-blind, placebo-controlled trial, we recruited patients aged at least 18 years with completely resected stage IB, II, and IIIA MAGE-A3-positive NSCLC who did or did not receive adjuvant chemotherapy from 443 centres in 34 countries (Europe, the Americas, and Asia Pacific). Patients were randomly assigned (2:1) to receive 13 intramuscular injections of recMAGE-A3 with AS15 immunostimulant (MAGE-A3 immunotherapeutic) or placebo during 27 months. Randomisation and treatment allocation at the investigator site was done centrally via internet with stratification for chemotherapy versus no chemotherapy. Participants, investigators, and those assessing outcomes were masked to group assignment. A minimisation algorithm accounted for the number of chemotherapy cycles received, disease stage, lymph node sampling procedure, performance status score, and lifetime smoking status. The primary endpoint was broken up into three co-primary objectives: disease-free survival in the overall population, the no-chemotherapy population, and patients with a potentially predictive gene signature. The final analyses included the total treated population (all patients who had received at least one treatment dose). This trial is registered with ClinicalTrials.gov, number NCT00480025. FINDINGS: Between Oct 18, 2007, and July 17, 2012, we screened 13 849 patients for MAGE-A3 expression; 12 820 had a valid sample and of these, 4210 (33%) had a MAGE-A3-positive tumour. 2312 of these patients met all eligibility criteria and were randomly assigned to treatment: 1515 received MAGE-A3 and 757 received placebo and 40 were randomly assigned but never started treatment. 784 patients in the MAGE-A3 group also received chemotherapy, as did 392 in the placebo group. Median follow-up was 38·1 months (IQR 27·9-48·4) in the MAGE-A3 group and 39·5 months (27·9-50·4) in the placebo group. In the overall population, median disease-free survival was 60·5 months (95% CI 57·2-not reached) for the MAGE-A3 immunotherapeutic group and 57·9 months (55·7-not reached) for the placebo group (hazard ratio [HR] 1·02, 95% CI 0·89-1·18; p=0·74). Of the patients who did not receive chemotherapy, median disease-free survival was 58·0 months (95% CI 56·6-not reached) in those in the MAGE-A3 group and 56·9 months (44·4-not reached) in the placebo group (HR 0·97, 95% CI 0·80-1·18; p=0·76). Because of the absence of treatment effect, we could not identify a gene signature predictive of clinical benefit to MAGE-A3 immunotherapeutic. The frequency of grade 3 or worse adverse events was similar between treatment groups (246 [16%] of 1515 patients in the MAGE-A3 group and 122 [16%] of 757 in the placebo group). The most frequently reported grade 3 or higher adverse events were infections and infestations (37 [2%] in the MAGE-A3 group and 19 [3%] in the placebo group), vascular disorders (30 [2%] vs 17 [3%]), and neoplasm (benign, malignant, and unspecified (29 [2%] vs 16 [2%]). INTERPRETATION: Adjuvant treatment with the MAGE-A3 immunotherapeutic did not increase disease-free survival compared with placebo in patients with MAGE-A3-positive surgically resected NSCLC. Based on our results, further development of the MAGE-A3 immunotherapeutic for use in NSCLC has been stopped. FUNDING: GlaxoSmithKline Biologicals SA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024025
003      
CZ-PrNML
005      
20170720123623.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(16)00099-1 $2 doi
035    __
$a (PubMed)27132212
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vansteenkiste, Johan F $u Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium. Electronic address: johan.vansteenkiste@uzleuven.be.
245    10
$a Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial / $c JF. Vansteenkiste, BC. Cho, T. Vanakesa, T. De Pas, M. Zielinski, MS. Kim, J. Jassem, M. Yoshimura, J. Dahabreh, H. Nakayama, L. Havel, H. Kondo, T. Mitsudomi, K. Zarogoulidis, OA. Gladkov, K. Udud, H. Tada, H. Hoffman, A. Bugge, P. Taylor, EE. Gonzalez, ML. Liao, J. He, JL. Pujol, J. Louahed, M. Debois, V. Brichard, C. Debruyne, P. Therasse, N. Altorki,
520    9_
$a BACKGROUND: Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made in adjuvant treatment. We aimed to assess the efficacy of the MAGE-A3 cancer immunotherapeutic in surgically resected NSCLC. METHODS: In this randomised, double-blind, placebo-controlled trial, we recruited patients aged at least 18 years with completely resected stage IB, II, and IIIA MAGE-A3-positive NSCLC who did or did not receive adjuvant chemotherapy from 443 centres in 34 countries (Europe, the Americas, and Asia Pacific). Patients were randomly assigned (2:1) to receive 13 intramuscular injections of recMAGE-A3 with AS15 immunostimulant (MAGE-A3 immunotherapeutic) or placebo during 27 months. Randomisation and treatment allocation at the investigator site was done centrally via internet with stratification for chemotherapy versus no chemotherapy. Participants, investigators, and those assessing outcomes were masked to group assignment. A minimisation algorithm accounted for the number of chemotherapy cycles received, disease stage, lymph node sampling procedure, performance status score, and lifetime smoking status. The primary endpoint was broken up into three co-primary objectives: disease-free survival in the overall population, the no-chemotherapy population, and patients with a potentially predictive gene signature. The final analyses included the total treated population (all patients who had received at least one treatment dose). This trial is registered with ClinicalTrials.gov, number NCT00480025. FINDINGS: Between Oct 18, 2007, and July 17, 2012, we screened 13 849 patients for MAGE-A3 expression; 12 820 had a valid sample and of these, 4210 (33%) had a MAGE-A3-positive tumour. 2312 of these patients met all eligibility criteria and were randomly assigned to treatment: 1515 received MAGE-A3 and 757 received placebo and 40 were randomly assigned but never started treatment. 784 patients in the MAGE-A3 group also received chemotherapy, as did 392 in the placebo group. Median follow-up was 38·1 months (IQR 27·9-48·4) in the MAGE-A3 group and 39·5 months (27·9-50·4) in the placebo group. In the overall population, median disease-free survival was 60·5 months (95% CI 57·2-not reached) for the MAGE-A3 immunotherapeutic group and 57·9 months (55·7-not reached) for the placebo group (hazard ratio [HR] 1·02, 95% CI 0·89-1·18; p=0·74). Of the patients who did not receive chemotherapy, median disease-free survival was 58·0 months (95% CI 56·6-not reached) in those in the MAGE-A3 group and 56·9 months (44·4-not reached) in the placebo group (HR 0·97, 95% CI 0·80-1·18; p=0·76). Because of the absence of treatment effect, we could not identify a gene signature predictive of clinical benefit to MAGE-A3 immunotherapeutic. The frequency of grade 3 or worse adverse events was similar between treatment groups (246 [16%] of 1515 patients in the MAGE-A3 group and 122 [16%] of 757 in the placebo group). The most frequently reported grade 3 or higher adverse events were infections and infestations (37 [2%] in the MAGE-A3 group and 19 [3%] in the placebo group), vascular disorders (30 [2%] vs 17 [3%]), and neoplasm (benign, malignant, and unspecified (29 [2%] vs 16 [2%]). INTERPRETATION: Adjuvant treatment with the MAGE-A3 immunotherapeutic did not increase disease-free survival compared with placebo in patients with MAGE-A3-positive surgically resected NSCLC. Based on our results, further development of the MAGE-A3 immunotherapeutic for use in NSCLC has been stopped. FUNDING: GlaxoSmithKline Biologicals SA.
650    _2
$a senioři $7 D000368
650    _2
$a antigeny nádorové $x imunologie $x metabolismus $7 D000951
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x imunologie $x metabolismus $x patologie $7 D002289
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunokonjugáty $x terapeutické užití $7 D018796
650    12
$a imunoterapie $7 D007167
650    _2
$a nádory plic $x farmakoterapie $x imunologie $x metabolismus $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x imunologie $x metabolismus $7 D009363
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x imunologie $x metabolismus $x patologie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Cho, Byoung Chul $u Yonsei University College of Medicine, Seoul, South Korea.
700    1_
$a Vanakesa, Tonu $u North Estonian Regional Hospital, Oncology Department, Tallinn, Estonia.
700    1_
$a De Pas, Tommaso $u Oncology Unit of Thymic Cancer, Rare Tumors and Sarcomas, Milan, Italy.
700    1_
$a Zielinski, Marcin $u Department of Thoracic Surgery, Zakopane, Poland.
700    1_
$a Kim, Moon Soo $u National Cancer Center, Goyang-si Kyunggi-do, South Korea.
700    1_
$a Jassem, Jacek $u Medical University of Gdansk, Gdansk, Poland.
700    1_
$a Yoshimura, Masahiro $u Hyogo Cancer Center, Akashi City, Hyogo, Japan.
700    1_
$a Dahabreh, Jubrail $u Athens Medical Centre, Marousi, Greece.
700    1_
$a Nakayama, Haruhiku $u Kanagawa Cancer Center, Yokohama City, Japan.
700    1_
$a Havel, Libor $u Department of Pneumology and Thoracic Surgery, Prague, Czech Republic.
700    1_
$a Kondo, Haruhiko $u Shizuoka Cancer Center, Tokyo, Japan.
700    1_
$a Mitsudomi, Tetsuya $u Aichi Cancer Center Hospital 1-1, Aichi, Japan.
700    1_
$a Zarogoulidis, Konstantinos $u Pulmonary Clinic, G Papanikolaou General Hospital of Thessaloniki, Aristotle University, Thessaloniki, Greece.
700    1_
$a Gladkov, Oleg A $u Regional Oncology Dispensary Medgorodok, Chelyabinsk, Russia.
700    1_
$a Udud, Katalin $u Korányi National Institute of Pulmonology, Budapest, Hungary.
700    1_
$a Tada, Hirohito $u Osaka City General Hospital, Osaka, Japan.
700    1_
$a Hoffman, Hans $u Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany.
700    1_
$a Bugge, Anders $u Oslo University Hospital, Rikshospitalet, Oslo, Norway.
700    1_
$a Taylor, Paul $u University Hospital of South Manchester, Manchester, UK.
700    1_
$a Gonzalez, Emilio Esteban $u Hospital Central de Asturias, Oviedo, Spain.
700    1_
$a Liao, Mei Lin $u Shanghai Chest Hospital, Shanghai, China.
700    1_
$a He, Jianxing $u The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China.
700    1_
$a Pujol, Jean-Louis $u Arnaud de Villeneuve Hospital, Montpellier, France.
700    1_
$a Louahed, Jamila $u GSK Vaccines, Rixensart, Belgium.
700    1_
$a Debois, Muriel $u GSK Vaccines, Rixensart, Belgium.
700    1_
$a Brichard, Vincent $u GSK Vaccines, Rixensart, Belgium.
700    1_
$a Debruyne, Channa $u GSK Vaccines, Rixensart, Belgium.
700    1_
$a Therasse, Patrick $u GSK Vaccines, Rixensart, Belgium.
700    1_
$a Altorki, Nasser $u Joan and Sanford I Weill Medical College of Cornell University, New York, NY, USA. $7 gn_A_00005018
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 17, č. 6 (2016), s. 822-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27132212 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124116 $b ABA008
999    __
$a ok $b bmc $g 1239706 $s 984938
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 17 $c 6 $d 822-35 $e 20160427 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace